Progress in Biosensors for the Point-of-Care Diagnosis of COVID-19

Sensors (Basel). 2022 Sep 29;22(19):7423. doi: 10.3390/s22197423.

Abstract

Coronavirus disease 2019 (COVID-19) is a highly virulent infection that has caused a pandemic since 2019. Early diagnosis of the disease has been recognized as one of the important approaches to minimize the pathological impact and spread of infection. Point-of-care tests proved to be substantial analytical tools, and especially lateral flow immunoassays (lateral flow tests) serve the purpose. In the last few years, biosensors have gained popularity. These are simple but highly sensitive and accurate analytical devices composed from a selective molecule such as an antibody or antigen and a sensor platform. Biosensors would be an advanced alternative to current point-of-care tests for COVID-19 diagnosis and standard laboratory methods as well. Recent discoveries related to point-of-care diagnostic tests for COVID-19, the development of biosensors for specific antibodies and specific virus parts or their genetic information are reviewed.

Keywords: SARS-CoV-2; antibody; antigen; coronavirus disease; diagnosis; handheld assay; immunosensor; lateral flow immunoassay; lateral flow tests; point-of-care test.

Publication types

  • Review

MeSH terms

  • Antibodies, Viral
  • Biosensing Techniques*
  • COVID-19 Testing
  • COVID-19* / diagnosis
  • Humans
  • Immunoassay
  • Point-of-Care Systems
  • SARS-CoV-2
  • Sensitivity and Specificity

Substances

  • Antibodies, Viral